Venatorx Pharmaceuticals Joins Antimicrobials Working Group
December 19, 2019
Venatorx Pharmaceuticals today announced that it joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies – along with laboratory and academic partners – that promotes a strong public-private partnership in order to ensure the medical countermeasures that protect public health are effective and readily available.
November 25, 2019
CARB-X is awarding Venatorx Pharmaceuticals up to US$4.1 million in non-dilutive funding, with the possibility of up to an additional US$8.9 million if certain project milestones are met, to develop a new class of oral antibiotics to treat infections caused by multi-drug-resistant (MDR) Neisseria gonorrhoeae.
September 4, 2019
With more than 20 years’ experience, Dr. Larsen is globally recognized as a leader in the area of public health preparedness. At Venatorx, Dr. Larsen will help translate Venatorx’s rich internal programs toward strategic public and private partnerships, and will help identify new growth opportunities for Venatorx.
August 29, 2019
Venatorx Pharmaceuticals initiated enrollment in its Phase 3 trial of cefepime/VNRX-5133. This Phase 3 clinical trial is a global randomized, double-blind, active controlled, non-inferiority study evaluating the efficacy, safety, and tolerability of cefepime/VNRX-5133 in adults with cUTI, including acute pyelonephritis.
August 21, 2019
Venatorx Pharmaceuticals added pharmaceutical industry veterans, Jennifer Ellis, Dr. Paul McGovern and Lauren P. Tornetta, to its development team. These appointments come as the Company continues to advance its portfolio of antibacterial and antiviral assets through their respective pre-clinical and clinical milestones.
August 6, 2019
Headquartered in the Philadelphia suburbs of Malvern, Pennsylvania, Venatorx has nearly doubled its headcount over the past year and is actively seeking motivated, passionate and entrepreneurial-minded professionals for open positions to support its aggressive strategic growth plan.
July 22, 2019
The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) will collaborate with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) and Venatorx Pharmaceuticals to develop a novel antibiotic to treat infections caused by bacteria resistant to currently available agents.
June 20, 2019
Venatorx Pharmaceuticals' founders, Christopher J. Burns, Ph.D., Daniel C. Pevear, Ph.D., and Luigi Xerri, Ph.D., received the Entrepreneur Of The Year 2019 Award in the Health and Life Sciences category in Greater Philadelphia.
June 17, 2019
Venatorx Pharmaceuticals will present ten posters featuring its two development-stage products, cefepime/VNRX-5133 and ceftibuten/VNRX-7145, at ASM Microbe 2019. Venatorx will also present an overview if its antibacterial agents portfolio during the Pharma Pipeline Update, concentrating on its orally bioavailable beta-lactamase inhibitor, VNRX-7145, during the New Agents Discovery Summary Session.
April 10, 2019
Venatorx Pharmaceuticals will have 12 poster presentations at ECCMID 2019 featuring cefepime/VNRX-5133 and ceftibuten/VNRX-7145.
April 4, 2019
Dr. Wittmer has more than 20 years’ experience and a demonstrated track record in leading development from early stages through to licensing, registration and commercialization of new therapeutics. In her role at Venatorx, Dr. Wittmer will oversee nonclinical and clinical development, as well as global regulatory affairs.
March 25, 2019
President and CEO, Christopher J. Burns, Ph.D., will present, "Discovery of VNRX-7145: A broad-spectrum orally bioavailable beta-lactamase inhibitor for highly resistant bacterial infections (“superbugs”)” during the First Time Disclosure of Clinical Candidates at the ACS National Meeting.
March 14, 2019
Recognition honors a CEO who has demonstrated visionary leadership and active participation to advance the life sciences and biotech industry.
February 28, 2019
The R01 grant will support therapeutic discovery for Gram-negative bacterial pathogens, including carbapenem-resistant Enterobacteriaceae, multi-drug resistant Acinetobacter baumannii and/or Pseudomonas aeruginosa. This initiative will also support Venatorx’s discovery programs targetVenatorx Pharmaceuticals Awarded NIAID R01 Grant to Uncover Determinants of Gram-Negative Permeabilitying novel antibacterial agents.
February 6, 2019
Chief Business Officer, Tony Meehan, MBA, PhD, will present attendees with an overview of Venatorx's pipeline and unique operating model on Monday, February 11, 2019 at 3:30pm ET in the Gramercy room at the New York Marriott Marquis.
January 3, 2019
The Antimicrobials Working Group (AWG) announced the addition of Venatorx Pharmaceuticals to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new addition brings AWG's membership to 15 antimicrobial drug companies.
Archive: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2011 | 2010 |